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From the Editor’s Desk
Technological advances are revolutionizing the way
in which we can diagnose and screen populations for
inborn errors of metabolism (IEM). The current state
of knowledge allows the diagnosis of many IEM by
detection of the aberrant gene. However, as multiple
genetic defects may result in the same biochemical
phenotype, most diagnosis of genetic defects in a
clinical setting are still accompanied by an abnormal
accumulation of the metabolites of the affected
pathways, or unusual metabolites from alternate
pathways.
The advances made in the diagnosis of IEM in recent
years have not only been in the field of discovering
new genes, but in technical ability to detect
intermediates of metabolism in smaller samples, with
greater efficiency and with fewer tests.

of lack of diagnostic facilities. The population
of Pakistan consists of a fine amalgamation of
people from diverse tribal, cultural, religious and
social backgrounds. Mortality and morbidity from
a vast number of medical and surgical conditions
is significant and well above compared to the
developed countries. Although a large component of
the human health problem in Pakistan is related to
infection, malnutrition and other preventable causes,
a significant proportion is linked to hereditary factors
reflecting in the form of chromosomal, single gene
and complex medical diseases.

Chromatographic techniques are ideal for separation
of compounds out of a complex mixture in a
biological matrix based on identification of compound
on retention time. Plasma amino acids analysis
by cation exchange chromatography and organic
acids determination by gas chromatography mass
spectrometry have been widely used for diagnosis of
aminoacidopathies and organic acidemias.

This issue is focused on the newly introduced
metabolic genetic testing services offered at
AKUH clinical laboratory in the Section of
Chemical Pathology for diagnosis of IEM. We
share relevant information about the service
offered and address the issues and challenges
for pathologist and physicians in Pakistan. In
addition the issue also includes tests that are being
offered in other sections. It is hoped that with
the introduction of these services, our efforts for
awareness and education of our physicians will
lead to substantial improvement in the diagnosis of
IEM in Pakistan.

In Pakistan, evidence on the underlying incidence
on the genetic disorder is lacking mainly because

Dr Aysha Habib Khan
Chemical Pathologist

Approach to a Sick Neonate with Hyperammonemia
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Diagnosis of Inborn Errors of Metabolism in
Pakistan: Issues and Challenges
Dr Aysha Habib Khan
Chemical Pathology

The scientific concept of inborn errors of
metabolism (IEM) was brought forward by Sir
Archibald Edward Garrod in early 1900s. The term
‘inborn errors of metabolism’’ was used to describe
the hereditary deficiency or alteration in enzyme
reactions. Although individual IEM are relatively
rare conditions; as a group they represent a vast and
diverse collection of diseases that are a significant
cause of morbidity and mortality worldwide.
The reports in literature often quote a cumulative
incidence varying between 1 in 1500 and 1 in 5000
live births.
In early 1960s, the concept of newborn screening
(NBS) was evolved. NBS allows screening of
newborns for disorders just after birth that can
cause severe illness or death unless detected
and treated early. For example phenylketonuria,
congenital hypothyroidism, congenital adrenal
hyperplasia (CAH), maple syrup urine disease
(MSUD) etc. Programs are designed to provide
early diagnosis and treatment before significant and
irreversible damage occurs. A comprehensive NBS

system/program consists of education, screening
(specimen collection, transportation, and testing),
follow-up of abnormal and unsatisfactory results,
confirmatory testing and diagnosis, treatment and
periodic outcome evaluation, quality assurance and
program evaluation, validity of testing systems,
efficiency of follow-up and intervention, and
assessments of long-term benefits to individuals,
families, and society. Public awareness coupled
with professional training and family education is
also a part of the complete NBS system. NBS has
been demonstrated to save lives and prevent serious
disability. Reports have shown its cost effectiveness
and it represents a public health success.
The criteria for inclusion of a test/disorder into a
newborn screening program continue to evolve
and are given in Table 1 and the disorders included
in NBS are given in Table 2. Pakistan has as yet
no newborn screening programme at the national
level. The health care system is mainly hospitalbased and primary health care facilities are
practically non-existent. A large proportion of

Table 1. Wilson and Jungner Criteria used to Justify Screening for a Specific Disorder*

1

The condition sought should be an important health problem

2

There should be an accepted treatment for patient with recognized disease

3

Facilities for diagnosis and treatment should be available

4

There should be a recognizable latent or early symptomatic stage

5

There should be a suitable test or examination

6

The test should be acceptable to the population

7

The natural history of the condition, including development from latent to declared disease should
be adequately understood

8

There should be an agreed policy on whom to treat as patients

9

The cost of case-finding (including diagnosis and treatment of patients diagnosed) should be
economically balanced in relation to possible expenditure on medical care as a whole

10 Case-finding should be a continuing process and not a ‘once and for all’ project
*Reproduced from Bulletin of the World Health Organization. Revisiting Wilson and Jugner in the genomic age: a review of screening
criteria over the past years.
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Table 2. Recommended uniform newborn screening panel; Good Laboratory Practices for Biochemical Genetic Testing and Newborn
Screening for Inherited Metabolic Disorders

Inborn errors of amino acid metabolism
Argininosuccinic aciduria
Citrullinemia, type I
Maple syrup urine disease
Homocystinuria
Classic phenylketonuria
Tyrosinemia, type I

Endocrine disorders
Primary congenital hypothyroidism
Congenital adrenal hyperplasia

Disorders of fatty acid oxidation
Carnitine uptake defect (carnitine transport defect)
Medium-chain acyl-CoA dehydrogenase deficiency
Very long-chain acyl-CoA dehydrogenase deficiency
Long-chain-L-3-hydroxyacyl-CoA dehydrogenase
deficiency
Trifunctional protein deficiency

Hemoglobin disorders
SS disease (sickle cell anemia)
S, beta-thalassemia

Disorders of organic acid metabolism
Propionic acidemia
Methylmalonic acidemia (methylmalonyl-CoA
mutase deficiency)
Methylmalonic acidemia (cobalamin disorders)
Isovaleric acidemia
3-Methylcrotonyl-CoA carboxylase deficiency
3-Hydroxy-3-methylglutaric aciduria
Holocarboxylase synthase deficiency
ß-Ketothiolase deficiency
Glutaric acidemia type I

Other conditions
Biotinidase deficiency
Cystic fibrosis
Classic galactosemia
Hearing loss
Severe combined immunodeficiencies

deliveries occur at home and majority of these
home deliveries are usually attended by unskilled
birth attendants. Pakistan also has a very high
consanguinity rate of 46-61 per cent due to strong
cultural preferences. The burden of inherited disease
is expected to be very high, and is considered to
be a major contributor to the high infant mortality
rate in Pakistan. Infants are not diagnosed early
and die without the benefit of available treatment.
In addition to this genetic counseling services are
not available and appropriate genetic advice is not
given to parents of these children so they often have
the additional problems of further affected infants
before the underlying disorder is detected.

not known. Some of the IEM like beta thalassemia,
G6PD, congenital hypothyroidism and CAH are
widely prevalent in our society.

There is a need to consider IEM as a potential
cause of any severe illness and to have a systemic
approach to diagnosis and management. However,
this was not possible as the diagnostic facilities
were non-existent. Due to the lack of diagnostic
facilities and absence of national registries for
disease prevalence of various inherited diseases are

Despite undergoing major revolutions in the
past years in the world, the field of inborn errors
of metabolism has so far been neglected in
Pakistan. The primary reason is non-availability
of the diagnostic facility, lack of expertise both
in terms of human resource as well as equipment
needed to perform the analysis. The equipment’s
are not only technically demanding but are very
expensive. In addition, there is no data to reflect
the prevalence of the defects from Pakistan.
However, the incidence appears to be high due to
high degree of consanguineous marriages. Aga
Khan University Hospital Clinical Laboratory has
now successfully acquired this technique and has
initiated the specialized testing for diagnosis of
IEM. The tests will be performed on state of art
equipment for diagnosis of amino acid disorders
and organic academia. The two techniques together
5
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can diagnose a number of disorders in a suspected
patient. Table 3 shows the IEM that has been
diagnosed from January to July 2013 in our lab.
Table 3. Aminoacidopathies and Organic acidemias Diagnosed
at AKUH Clinical Laboratory (20th January 2013-3rd July 2013)

N= 306,

Aminoacidopathies/
Organic Acidemia

Total No. of Positive cases

25

Methylcobalmin defect or
deficiency

7

2-methyl,-3-OH butryl Co A
dehydrogenase deficiency

2

Hyperphenylealalinemia

1

Cystathionine beta synthetase
deficiency

3

Propionic acidemia

2

Ethylmalonic aciduria

1

Urea cycle disorder

2

MSUD

1

Biotinidase or holocarboxylase
deficiency

1

Isovaleric acidemia

2

Glutaric aciduria

1

2-methyl butyryl glycine
aciduria

1

Lysinuric protein intolerence

1

Physicians play an important role in the
recognition of infants who may have an IEM and
in the initial evaluation and stabilization of these
patients and specific treatment. At the same time
Chemical Pathologist has a great responsibility
of appropriately diagnosing these conditions. A
very close liaison is required between chemical
pathologist and treating physician. Clinicians
should provide related history of the patient to
the Clinical Laboratory that helps in appropriate
processing of the specimen and analysis; hence
report interpretation and correct diagnosis by
Chemical Pathologist.
It is important to progressively bring the inborn
errors of metabolism to a higher level among
health priorities. Challenges to the progress of the
IEM field include huge disparities in our ethnic
populations, high prevalence of malnutrition
and infections, co-existence of very different
models of public health services, unstable socioeconomic and political conditions, and difficulties
in integrating the various stakeholders. There is a
need to develop activities for provision of health
services, education and research as an integrated
package, increase training of human resources,
expansion of access to diagnostic tests, and use
of the neonatal screening framework to expand
the provision of services. In a country with no
IEM centers, there is a major need for such
groups to work in collaboration, complementing
each other’s capabilities, providing training,
and developing joint projects. The integration of
these groups into a large transnational network of
reference centers would be our major aim for the
coming years.

Inherited Metabolic Disorders - Presenting as
Metabolic Emergencies
Dr Bushra Afroze
Department of Paediatrics and Child Health

“When you hear hoofs, think of horses”…but do
not forget Zebras!
Inborn errors of metabolism (IEM) comprise a large
group of inherited disorders resulting from either an
enzyme or a co-factor defect. Individual disorders in
6

the large group of IEM are rare; however collective
incidence of IEM is 1 in 5000 live birth, which is
same as the incidence of congenital hypothyroidism.
A significant proportion of IEM present during
the neonatal or early childhood period with severe
acute clinical manifestation. Unfortunately, for most
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Table 1. Clinical Presentation of IEM

disorders the early symptoms are non-specific like
lethargy, refusal to feed, vomiting and tacypnea or
apnea (Table 1). This often leads to consideration
of more common causes like birth asphyxia, sepsis
and pneumonia at the initial assessment of such
patients. IEM are often either completely not
considered or considered very late. This leads to
delay in diagnosis and appropriate management and
eventually result in devastating outcomes.
Inherited metabolic diseases with acute
severe manifestations can be divided into five
categories:
(1)
(2)
(3)
(4)
(5)

Disorders of the intoxication type
Disorder with reduced fasting tolerance
Disorders with disturbed energy metabolism
Disorders of neurotransmission
Disorders in which no specific emergency 		
treatment is available.

Diagnostic emergency laboratory evaluation
should cover all differential diagnoses that
are therapeutically relevant and should always
include blood glucose, serum ammonia, serum
lactate and acid base status, serum electrolytes for
anion gap and urine for ketones. Results of these
should be available to treating physician within
30 minutes. According to the clinical situation

and biochemical derangement, special metabolic
investigations must be initiated in parallel, which
include acylcarnitine profiling with tandem
mass spectrometry (in plasma or dried blood
spots) and analysis of amino acids in plasma
and of organic acids in urine. The results of all
laboratory investigations relevant to the diagnosis
of metabolic disorders for which specific
emergency therapy exists should be available
within 24 hour. Emergency treatment of metabolic
disorders consists of symptomatic treatment,
which is applied regardless of the underlying
disorder, which does not require knowledge
of the nature of the underlying disorder in the
critical phase of stabilization. However, details
of the diagnosis and in-depth knowledge of the
disease in a particular patient is needed for the
disease specific long-term treatment and better
outcome. The long-term outcome is inversely
related to the time between the onset of symptoms
and the start of specific emergency treatment
in the critical phase of stabilization. This often
requires the initiation of therapy before the exact
diagnosis is known and rapid initiation of specific
investigations. Thus physicians having first
encounter with such patients have an important
role in recognizing the below-mentioned groups
of IEM, (Table 2) getting appropriate labs and
initiating right emergency treatment.
7

DECEMBER 2013
Table 2. Categories of IEM with few examples
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1. Disorders of the Intoxication Type
This group comprises urea cycle disorders, organic
acidopathies, amino acidopathies, fatty acid
oxidation defects, galactosaemia and hereditary
fructose intolerance.
Clinical presentation: Children with disorders
of the intoxication type are typically born after
an uneventful pregnancy and show a symptomfree period after birth. The patient with a disorder
of protein or fat catabolism typically develops
symptoms in the first few days of life during the
naturally occurring catabolic period. Symptoms
include poor sucking, vomiting, and lethargy
progressing to coma. Sepsis is a common diagnosis
considered in this situation. After the neonatal
period, catabolism is rare in the first months of life.
Towards the end of the first year of life, however
the risk of metabolic decompensation increases as a
consequence of episodes of infection and protein-rich
meals.
Principles of therapy: The oral intake of toxic
precursors (protein in cases of disorders involving
protein metabolism and fat in disorders involving
fat metabolism) must be stopped. The endogenous
catabolism of protein or fat must be reversed in
disorders of protein or fat degradation. Specific
detoxification measures should be instituted if
available. However, neither protein nor fat can be
stopped from diet for more than 48 hours. After
initial 48 hours, only the involved amino acid in
protein metabolic disorders and long chain length
fatty acids in fatty acid oxidation defects are
restricted based on the diagnosis established based
on acylcarniitne, plasma amino acid and urine
organic acids results.
2. Disorders with Reduced Fasting Tolerance
This group includes disorders of glucose
homeostasis (glycogen storage diseases, disorders
of gluconeogenesis, congenital hyperinsulinism)
and disorders in which ketone bodies cannot be
synthesized for use as alternative substrates once
glycogen stores are exhausted (fatty acid oxidation
defects, disorders of ketogenesis and ketolysis).
Clinical presentation: These disorders become
symptomatic when the intervals between meals
become longer or in the case of limited glucose
supply, for example when vomiting or anorexia result
from inter-current infection. A few patients may
present in the neonatal period, however most present

VOL. 39, ISSUE 2

after infancy when nocturnal feeding is usually not
as frequently given as in early infancy.
Principles of therapy: Glucose administration at
the rate of the hepatic glucose production is basically
sufficient to meet caloric demands in these disorders.
Patients with congenital hyperinsulinism may
need glucose much higher than the hepatic glucose
production, which needs to be adjusted based on
individual patient’s requirement. Forced anabolism
is not needed in these disorders, as there is no
intoxication due to catabolism.
3. Disorders with Disturbed Mitochondrial 		
Energy Metabolism
This group comprises defects of the pyruvate
dehydrogenase complex and the respiratory chain.
Clinical presentation: Generalized lack of energy
often impairs intrauterine growth and development.
Due to presence of prominent lactic acidosis,
perinatal asphyxia is often considered as the initial
diagnosis in affected neonates.
Principles of therapy: Correction of acidosis is
a major goal. Glucose supply has to be limited,
especially in defects of the pyruvate dehydrogenase
complex, because a high glucose supply may
exacerbate lactic acidosis.
4. Disorders of Neurotransmission
Acute emergency treatment is available in two
disorders of neurotransmission: vitamin B6- and
folinic acid-responsive seizures.
Clinical presentation: present immediately after birth
with an epileptic encephalopathy, which is unresponsive
to conventional anti-convulstants therapy.
Principles of therapy: In every newborn with
epileptic encephalopathy a trial with intravenous
pyridoxine and folinic acid should be performed.
5. Disorders with No Specific Emergency 		
Treatment available
There are many other metabolic disorders that
may present with acute, often encephalopathic,
manifestations (nonketotic hyperglycinaemia,
sulphite oxidase deficiency) or that usually follow a
chronic progressive course but may worsen during
episodes of acute illness (congenital disorders of
glycosylation, peroxisomal disorders).
9
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Role of Biochemical Genetics Laboratory in
Evaluation of IEM
Dr Farhan Javed Dar
Chemical Pathology

and specialized tests at the time of presentation.
Laboratory evaluation for inborn errors of
Samples for specialized tests should be processed
metabolism (IEM) should be undertaken in all
and stored appropriately for further testing if
patients with suggestive history examination,
indicated.
and/or abnormalities of routine laboratory tests.
Patients with life-threatening illness should undergo
In suspected patient of IEM, following are the first
concurrent evaluation for other conditions in
line investigations offered at Clinical Laboratory of
the differential diagnosis such as sepsis, cardiac
Aga Khan University Hospital. These tests provide a
disease, etc. An optimal outcome of a child with
valuable clue of establishing a differential diagnosis
IEM depends upon early recognition of the signs
as shown in Table 1.
and symptoms of metabolic disease followed by
prompt laboratory evaluation and
Table 1. Distinguishing Biochemical Findings of IEM
referral to a center familiar with
the management of these disorders.
Delay in diagnosis may result in
acute metabolic decompensation,
progressive neurologic injury, or
death.
Laboratory investigations can be
tiered up to three levels which help
in making diagnosis of IEM in a
patient.
1. Metabolic screening panel
		 consisting of initial
		laboratory tests
2. Specialized testing consisting
		 of qualitative detection of
		 urine organic acids and 		
		 quantification of amino acids
		 in plasma, urine, CSF, etc
3. Enzyme assay
1. Metabolic Screening Panel:
First Line Investigations for
Diagnosis of IEM

MSUD: Maple syrup urine disease,

-

usually absent

OA:

Organic acidemia,

±

sometimes present

UCD:

Urea cycle disorders,

+

usually present

DCM:
Disorders of carbohydrate
		 metabolism,

++ always present

FAO:

A appropriate
H inappropriately high
L inappropriately low

An abnormal laboratory value may be the first
finding noted that suggests an IEM. The first line
investigations are very important diagnostic clue
for further confirmatory laboratory investigations
in suspected patient of IEM. However, in some
disorders, these laboratory abnormalities are
only present during the episode of metabolic
decompensation. If possible, blood and urine
samples should be obtained for both the initial
10

Fatty acid oxidation

Complete Blood Count: provides a clue to sepsis,
which may be the trigger for a metabolic crisis. IEM
patient may have anemia, thrombocytopenia, or
pancytopenia.
Arterial blood: is used to detect acid-base
disturbances. Metabolic acidosis with an increased
anion gap is commonly associated with organic
acidemias. It may also may be present in amino

DECEMBER 2013

acid disorders, disorders of pyruvate metabolism,
mitochondrial disorders, and disorders of
carbohydrate metabolism. Respiratory alkalosis is
commonly seen in urea cycle disorders as a result of
hyperammonemia.
Serum Electrolytes: Measurement of serum
electrolytes is necessary to calculate the anion gap.
A metabolic acidosis with an increased anion gap is
commonly seen in organic acidemias.
Plasma lactate: Lactic acidosis caused by abnormal
oxidative metabolism is a frequent finding
in mitochondrial disorders, glycogen storage
disorders, and disorders of gluconeogenesis.
Plasma ammonia: Significant elevations in
ammonia are most commonly associated with
urea cycle disorders and certain organic acidemias
(particularly propionic and methylmalonic
acidemias). High blood levels of ammonia may also
be found in other amino acid disorder and other
fatty acid oxidation defects.
Plasma Glucose: Hypoglycemia is typical of
disorders of ketogenesis e.g. fatty acid oxidation
disorders, glycogen storage disorders, and disorders
of fructose metabolism. It also may occur in amino
acid disorders, organic acidemias, and mitochondrial
disorders.
Urine detail report: Urine detail report gives
clue to certain IEM disorders e.g. urine specific
gravity lowers down in number of IEM disorders
having renal tubular dysfunction. The urine pH is
also helpful in determining the cause of metabolic
acidosis. Presence of ketones may also suggest
IEM. Ketones are usually presents in patients with
hypoglycemia and glycogen storage disease, organic
academia.
Urine reducing substances: Reducing substances
in the urine is a clue to certain IEM if the urine
dipstick is negative for glucose. Positive result may
indicate carbohydrate intolerance disorder (e.g.
galactosemia, hereditary fructose intolerance) or
an amino acid disorder. However, the absence of
reducing substances in the urine does not exclude
these disorders.
2. Second Line Tests:
Specialized tests are performed on the basis of
clinical context and first line of investigations.
These tests include quantitation of amino acids,
organic acids, carbohydrate and other metabolites,
mucopolysaccharide separation and speciation, etc.
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Few frontline laboratory tests in this tier are:
Gas chromatography mass spectrometry
(GCMS): of urine for diagnosis of organic
acidemias Plasma amino acids and acyl-carnitine
profile: by tandem mass spectrometry (TMS)
for diagnosis of organic acidemias, urea cycle
defects, aminoacidopathies and fatty acid
oxidation defects.
High performance liquid chromatography
(HPLC): for quantitative analysis of amino acids in
blood and urine; required for diagnosis of organic
acidemias and aminoacidopathies
CSF aminoacid analysis: CSF Glycine levels
elevated in non-ketotic hyperglycinemia
Urinary orotic acid- in cases with hyperammonemia
for classification of urea cycle defect
Urinary Succinylacetone in cases of tyrosinemia.
Plasma very long chain fatty acid (VLCFA) levels:
elevated in peroxisomal disorders
Urine chromatography by thin layer chromatography
and liquid chromatography mass spectrometry
(LCMS); for qualitative and quantitative detection of
sugars.
Urine purines and pyrimidines analysis by Gas
chromatography mass spectrometry.
3. Definitive Diagnostic Tests; Enzyme Assay:
To confirm the disorder detected on specialized tests,
a specific enzyme assays in leucocytes, plasma/serum
or red cells, immunoassays and DNA/ Mutation
based analysis is required. Utility of enzyme assay in
establishing diagnosis of IEM is confirmative. These
tests are available at highly specialized centers for
IEM.
Biochemical Metabolic Testing At Clinical
Laboratory AKUH:
Other than first line investigations (metabolic
screening panel) specialized tests have been
introduced at Clinical Laboratory AKUH. These
tests are useful in diagnosis of disorders of amino
acids, urine organic acids and some fatty acid
oxidation defects. The specialized tests for IEM
available are:
Plasma, Urine and CSF Amino Acids (Quantitative,
Method: cation-exchange HPLC)
Urine Organic Acid (Qualitative, Method: GCMS)
Urine Succinylacetone (Quantitative, Method: GCMS)
11
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Amino Acid Chromatography for the
Diagnosis of Inborn Errors of Metabolism
Azeema Jamil
Chemical Pathology

Amino acids are the building blocks of proteins
and have many functions in the body. Amino
acid disorders are a group of inherited metabolic
conditions, each associated with a specific enzyme
deficiency involved with protein metabolism
that causes the accumulation of amino acids or
metabolites in blood and urine. The accumulated
compounds and metabolites are toxic, resulting in the
clinical features of these disorders.
Using amino acid chromatography 22 amino
acids can be quantified. Of these nine are
essential amino acids. Amino acids eluted on
chromatogram after analysis of standard prepared
are listed in Table 1.
Table 1. List of amino acids quantified in Clinical Laboratory
of AKUH

Fig. 1. Analysis of Amino Acids is in progress
Courtesy of Section of Biochemical Genetics Laboratory,
Aga Khan University

analysis of amino acid mixture. It gives fully
automatic and high speed analysis which is
very sensitive. Basic principle of instrument is
cation-ion exchange high performance liquid
chromatography (HPLC).
The sample containing a mixture of amino acids
is loaded into a column of cation-exchange resin.
The sample is moved down in the controlled
column temperature along with buffer of
required pH which is programmed to produce
the required separation. At high temperature of
reaction coil, ninhydrin reacts with amino acids
present in the eluent to form colored compound.
In elute, the amount of colored compound
produced is directly proportional to the quantity
of amino acids present. The amount of each
colored compound is determined at two different
wavelengths, 440nm and 570nm. At 440 nm
hydroxproline and proline is measured, the rest
are estimated at 570 nm.

Principle of Amino Acid Quantification:
The amino acid analyzer (Shown in Fig. 1)
is designed to provide accurate quantitative

12

Estimation of one sample takes almost 3 hours to
complete. The unit of reporting is µmol/l (Table 2) and
age specific reference ranges are in used. The standard
chromatogram of plasma amino acid is shown.
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Table 2: Marked elevation of phenylalanine is noted in the
amino acid quantification report below which is suggestive of
hyperphenylalaninemia.

Plasma Amino Acid Quantification
Test

Result

Unit

Normal Range

Taurine
Aspartate
Threonine
Serine
Aspargine
Glutamate
Glutamine
Glycine

36
1
43
108
43
18
299
153

µmol/L
µmol/L
µmol/L
µmol/L
µmol/L
µmol/L
µmol/L
µmol/L

(19 139)
(0 - 16)
(36 - 136)
(42 - 174)
(26 - 70)
(24 - 68)
(337 - 709)
(74 - 290)

Alanine
Citrulline
Valine
Cystine
Methionine
Isoleucine
Leucine
Tyrosine
Phenylalanine
Ornithine
Lysine
Histidine
Arginine
Proline

109
20
92
28
5
28
63
35
1201
36
192
40
26
99

µmol/L
µmol/L
µmol/L
µmol/L
µmol/L
µmol/L
µmol/L
µmol/L
µmol/L
µmol/L
µmol/L
µmol/L
µmol/L
µmol/L

(144 - 348)
(6 - 34)
(79 - 267)
(43 - 67)
(9 - 29)
(32 - 92)
( 53 - 149)
(14 - 114)
(26 - 70)
(9 - 105)
(56 - 146)
(30 - 110)
(18 - 78)
(53 - 201)

Organic Acid Chromatography for the
Diagnosis of Inborn Errors of Metabolism
Farhat Jahan
Chemical Pathology

Organic acids are compounds with acidic
properties and are intermediary or end product
of metabolism Fig. 1. An enzyme defect in a
metabolic pathway can lead to accumulation

Principle of Detection of Urine Organic Acids:
Organic acid analysis by Gas Chromatography-Mass
Spectrometry (GC-MS) is critical for the diagnosis of
organic acidurias. This technique
is a combination of two powerful
techniques: Gas chromatography
and Mass spectrometry. GC can
separate volatile and semi-volatile
compounds with great resolution
whereas MS can provide detailed
structural information on most
compounds such that they can be
exactly identified.

The process involves processing
of sample followed by injection
into the column via injector (Fig.
Fig. 1. Wide range of Compounds produce Organic Acids during their Metabolism
2). The sample is then carried into
the column by carrier gas ‘helium’
and increased excretion of one or more of
and the compounds in sample are separated on the
organic acids in urine resulting in Organic
basis on their boiling points and chemical structure
Acidurias, that may lead to acute life-threatening
as the column is heated. Effluent from GC passes
illness, developmental delays, and metabolic
through transfer line into the Ion trap/ Ion source
decompensation. Urine organic acid analysis
where molecules then undergo electron ionisation
is an essential component of the workup of the
(EI). These ions are then analysed according to their
patient suspected to have an inborn error of
mass to charge ratio and are detected by electron
metabolism.
multiplier which produces a signal proportional to
13
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Fig. 3. Urine Organic Acid Chromatogram showing Markers of Hyperphenylalaninemia Courtesy of Section of Biochemical Genetics Laboratory,
Aga Khan University
Fig. 2. Analysis of Urine Organic Acid is in Progress
Courtesy of Section of Biochemical Genetics Laboratory, Aga Khan University

ions detected resulting in a unique spectrum. Urine
organic acid chromatogram achieved in a patient
with ‘hyperphenylalaninemia’ is shown in Fig. 3.

Sample preparation is done in batches which take almost
3.5 hours and the sample analysis time on instrument is
35 minutes. All the peaks in chromatograms are matched
with available organic acid libraries. After skillful
interpretation the accurate diagnosis is made.

Polymorphism in Methylenetetrahydrofolate
Reductase (MTHFR) Gene
Zahida Amin Mir and Lamia Altaf
Molecular Pathology

Methylenetetrahydrofolate Reductase (MTHFR)
is a rate-limiting enzyme in the methyl cycle.
This enzyme is encoded by the MTHFR gene
on chromosome 1 location p 36.3. It plays a
vital role in folate metabolism, by catalyzing
reduction of 5,10- methylenetetrahydrofolate to
5-methylenetetrehydrofolate (Fig. 1), which is

Fig. 2. Overview of the Human Folic Acid Metabolic Pathway and the
role of MTHFR S-adenosyl Methionine (SAM), S-adenosyl Homocysteine
(SAH), Dihydrofolic Acid (DHF), Tetrahydrofolic Acid (THF), DihydroFolate (DHF), Methionine Synthase (MTR), Thymidylate Synthase (TS)
Fig. 1. Schematic diagram of the Reductive Carbon-nitrogen Bond
Cleavage (represented by wavy line) Catalyzed by Methylenetetrahydrofolate Reductase

required for the multistep process that converts
the amino acid homocysteine to another amino
acid, methionine (Fig. 2). As human body requires
methionine for protein synthesis, this is a critical
enzyme. Mild to severe loss of enzyme activity
results in elevated levels of homocysteine in
14

blood and/or urine, leading to development delays
and mental retardation. Elevated homocysteine
levels may also cause irritation of blood vessels
and clotting of blood in the veins. As a result of
which, coronary artery disease leading to a heart
attack or stroke may occur. In addition due to
MTHFR deficiency body is unable to absorb folic
acid which is essential for the development and
health of the fetus.
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MTHFR Gene Polymorphism

MTHFR Genotyping

The two major single nucleotide polymorphisms
(SNP) associated with MTHFR are C677T and
A1298C.

DNA is isolated from blood and subjected to in vitro
amplification for the desired regions of the MTHFR
gene codons 677 and 1298 using sequence specific
primers. The amplified products are analyzed by
gel electrophoresis followed by ethidium bromide
stainingThe amplified PCR products (MTHFR) are
subjected to Hinf I for codon 677 and Mbo II for
codon 1298 restriction enzyme digestion at 37°C
overnight. The PCR products subjected to enzyme
digestion are visualized on 3% agarose gel stained
with ethidium bromide.

C677T SNP (Ala222Val)
The MTHFR nucleotide at position 677 in the
gene has two possibilities, C (cytosine) or T
(thymine). C at position 677 (leading to an alanine
at amino acid 222) is the normal allele. The 677T
allele (leading to a valine substitution at amino
acid 222) encodes a thermolabile enzyme with
reduced activity. Individual with two copies of
677C (677CC) have the “normal” or “wildtype”
genotype. 677TT individuals (homozygous) are
said to have mild MTHFR deficiency. 677CT
individuals (heterozygotes) are almost the same as
normal individuals because the normal MTHFR
compensate for the thermolabile MTHFR.
A1298C SNP (Glu429 Ala)
At nucleotide 1298 of the MTHFR, there are
two possibilities: A or C. 1298A (leading to a
Glu at amino acid 429) is the most common
while 1298C (leading to an Ala substitution at
amino acid 429) is less common. 1298AA is the
“normal” homozygous, 1298AC the heterozygous
and 1298CC the homozygous for the “variant”.
The protein encoded by 1298C cannot be
distinguished from 1298A in terms of activity,
thermolability, flavin adenine dinucleotide
release, or the protective effect of 5-methyl-tetra
hydro folic acid. The C mutation does not appear
to affect the MTHFR protein. It does not result
in thermolabile MTHFR and does not appear to
affect homocysteine levels.

For MTHFR 677, the PCR yielded a 198 bp product,
which on digestion with Hinf I produced a 175 and
23 bp fragments for TT condition (homozygous
polymorphic) and a 198,175 and 23 bp fragments
for CT condition (heterozygous polymorphic). An
undigested product length of 198 bp was retained
by the wild types (Fig. 3A). For MTHFR 1298
genotyping PCR conditions were same as that
of MTHFR 677 and the product yielded a 241bp
fragment. AA genotype (wild type) on digestion
with Mbo II, yield two fragments of sizes 204 and
37, CC genotype (homozygous polymorphic) after
digestion retained the 241 fragment size and AC
genotype (heterozygous polymorphic) produced
three fragments of size 241,204 and 37bp (Fig. 3B).

Fig. 3A. Gel Electrophoresis
showing C677T Single Nucleotide
Polymorphism

Fig. 3B. Gel Electrophoresis
showing A1298C Single Nucleotide
Polymorphism

Diagnosis of Tyrosinemia Type I
Nasir Ali
Chemical Pathology

Tyrosinemia type I is an autosomal recessive
disorder characterized by lack of the enzyme
fumarylacetoacetate hydrolase (FAH), which is
needed to break down the amino acid tyrosine.
Failure to properly break down tyrosine
leads to abnormal accumulation of tyrosine

and its metabolites; succinylacetone and
succinylacetoacetate in the liver, resulting in severe
liver disease. (Fig. 1) Tyrosine may also accumulate
in the kidneys and central nervous system.
Others types of tyrosinemia includes type II
15
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within the first few months of life and may include
diarrhea, bloody stools, failure to thrive, vomiting,
lethargy, irritability, and a “cabbage-like” odor to
the skin or urine. If untreated, liver problems such as
hepatomegaly jaundice, easy bleeding/bruising, and
swelling of the legs/abdomen are common. Kidney
problems can cause rickets and delays in walking.
Without treatment, liver and kidney problems usually
lead to death. Periodic episodes of pain/weakness
(particularly in the legs), tachycardia, breathing
problems, seizures, and coma may occur.
The diagnosis of tyrosinemia is confirmed by
measuring the elevated levels of tyrosine often with
methionine and perhaps generalized aminoacids
in the blood and organic acids along with
‘succinylacetone’ in the urine. Enzyme testing and
genetic testing of the FAH gene may also be used to
confirm the diagnosis.

Fig. 1. Pathway for Degradation of Tyrosine showing the Defect in
Tyrosinemia Type 1 and the point of Action of NTBC

and III. Tyrosinemia type II, also known as
oculocutaneous tyrosinemia, characteristically
effects the cornea and skin, and is caused by
deficiency of tyrosine aminotransferase, which acts
at the first step in tyrosine catabolism. Tyrosinemia
type III is a rare disorder caused by deficiency of
4-hydroxyphenylpyruvate dioxygenase (4HPPD).
In addition to the three inherited disorders, transient
tyrosinemia of the newborn is the major cause of
tyrosine elevations detected on newborn screening.
Patient with tyrosinemia may present with symptoms

Only 2-5 ml spot (untimed) urine is required for
analysis of succinylacetone. Succinylacetone
is photosensitive therefore protection of urine
from light is advised. It can easily be done by
wrapping the container with dark plastic bag. Urine
succinylacetone is reported in mmol/mol creatinine
and is normally not detected in urine.
Once diagnosed, children with tyrosinemia
are treated with a medication called nitisinone
(previously called NTBC). A diet low in tyrosine,
phenylalanine, and methionine, and a special medical
formula is often recommended. In the long term,
individuals with liver damage or liver cancer may
require a liver transplant. Treatment can prevent
liver disease, kidney problems, and the neurological
problems that can be associated with tyrosinemia.

Highlights of Metabolic Services at Clinical
Laboratory of AKUH
Azeema Jamil, Rakshanda Mahar, Farhat Jahan, Nasir Ali
Chemical Pathology

Specimen Collection and Submission
Three types of specimens can be submitted at AKUH
Clinical Laboratory to perform specialized tests
related to amino acid, urine organic and fatty acid
oxidation disorders. For plasma amino acid detection
16

in blood, only a few millilitres, 2-4 ml of venous
blood in tube containing lithium heparin (green top)
is required. Fasting specimen (at least two hours for
infants and four hours for children) is preferred to
avoid the increase of most amino acids after a meal
intake.
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Only 2-5 ml of urine collected in a clean sterile
bottle is required for amino acid quantification in
urine, qualitative detection of organic acids and
quantification of succinylacetone. Urine can be
collected anytime during the day. However, an
early morning sample of urine is preferred.
The third specimen type in which quantification
of amino acid is performed is Cerebrospinal fluid
(CSF). The CSF is collected by the patient’s
concerned doctor in a sterile container/ microtube. Only 0.5 ml clear CSF is required for the
analysis along with 2 ml whole blood collected
in lithium heparinized tube. Plasma amino acid
quantification is required to calculate the ratio
between CSF and plasma amino acids. For
analysis minimum acceptable volume of separated
plasma, urine and CSF is 0.2 ml (200 µl). It
is advisable to collect sample for laboratory
tests related to IEM when symptoms are most
pronounced in patient and before start of any
treatment.
Specimen Transportation
For transportation of above specimens few
important things must be followed. The most
important one for plasma amino acid is that blood
should be transported to laboratory on ice within
four hours where it should be centrifuged and
separated plasma should be stored at minus 20°C. If the sample is collected outside AKUH
then separated plasma should be transported to
laboratory in dry ice. Freezing of whole blood
collected in tube containing lithium heparin is
prohibited.
Urine sample should also be frozen if the
transportation time of more than four hours is
required. For succinylacetone one more thing
should be taken care of that is to avoid any light
exposure.
CSF is very precious sample to analyze and it
should be sent on ice immediately as collected. If
CSF has to be transported from outside AKUH it
should be transported in dry ice.

Specimen
There is a sample rejection policy at AKUH
clinical laboratory where hemolyzed blood
sample, stained CSF and unfrozen specimen
received at laboratory are rejected. All specimens
received at the processing bench in the Section of
Chemical Pathology are checked and received as
per specimen collection policies. If any specimen
is rejected such as specimen collected in wrong
tube, a telephone call is made to the provided
contact number given at time of specimen
deposition for request of fresh sample.
Specimen Reporting
The turnaround time for amino acid quantification
is 10 days and for urine organic acid is seven days
after receiving the sample at Clinical Laboratory
of AKUH. However, the stat testing of these
tests within three days can be accomplished
on physician request. Urine succinylacetone is
performed on every Wednesday and the reporting
is available on next Wednesday.
Coordination between Laboratory and treating
Physician
All positive cases of IEM are discussed and
reported to concerned physicians.
Filling of History Form
Physicians need to fill the patient’s history
form for all the tests being performed at the
biochemical genetic lab for the diagnosis of IEM.
This history form contains information regarding
patient’s current health sign and symptoms along
with patient’s detailed clinical history.
This history form is available at the Clinical
Laboratory reception within AKUH as well
as in all; Pediatric Ward, NICU, ER, etc in
AKUH campus. It is also available at all
AKUH phelebotomy centers within and outside
Karachi.
This is the sample copy of the form.

17
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Congenital Hypothyroidism
Dr Noreen Sherazi
Chemical Pathology

Congenital hypothyroidism (CH) is one of the most
common preventable causes of mental retardation
that occurs due to thyroid hormones deficiency at
birth. In most cases, the disorder is permanent. Less
commonly, the altered neonatal thyroid function is
transient, attributable to the transplacental passage of
maternal medication, maternal blocking antibodies,
or iodine deficiency or excess.

The signs and symptoms in CH may be so subtle
that they can be easily missed. Excessive sleeping,
reduced interest in nursing, poor muscle tone,
low or hoarse cry, infrequent bowel movements,
exaggerated jaundice, and low body temperature
If fetal deficiency was severe because of complete

CH is caused by an absent or defective thyroid gland
classified into agenesis (22-42 per cent), ectopy (3542 per cent) and gland in place defects (24-36 per
cent). There could be genetic defects of thyroxine
or triiodothyronine synthesis within a structurally
normal gland. In a small proportion of cases of
CH, the defect is due to a deficiency of thyroid
stimulating hormone (TSH), either isolated or as part
of CH. (Fig. 1)

CONGENITAL
HYPOTHYROIDISM (CH)
Normal Thyroid
Gland

Congenital
Hypothyroidism

Thyroid may be
missing, misplaced, too
small or not making
enough harmone

Thyroid Hormone

Normal Cell and Body
Function

Thyroid Hormone

Multiple Health and
Growth Problems

Fig. 1. Metabolic Defect in Congenital Hypothyroidism
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Fig. 2. Features of congenital hypothyroidism

absence (athyreosis) of the gland, physical features
may include a larger anterior fontanel, persistence of
a posterior fontanel, an umbilical hernia, and a large
tongue (macroglossia) (Fig. 2).
In the developed world, nearly all cases of CH are
detected by the newborn screening program. It is
based on measurement of TSH or thyroxine (T4)
on the second or third day of life. There could be
high TSH or low T4 in individuals with CH. Two
screening strategies for the detection of CH have
evolved, a primary TSH/backup T4 method and a
primary T4/backup TSH method. In addition, an
increasing number of programs use a combined
primary TSH plus T4 approach. This represents
the ideal screening approach, especially once it is
possible for FT4 to be measured accurately and
cost-effectively in the eluates from filter-paper
blood spots. Every infant should be tested before
discharge from the nursery, optimally by 48 hours
to four days of age. Specimens collected in the first
24 to 48 hours of life may lead to false-positive TSH
elevations when using any screening test approach.
Newborn screening test results must be
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communicated rapidly back to the physician or
hospital identified on the screening filter-paper
card.
Most of the hereditary types of CH are inherited
in an autosomal recessive manner with an
incidence of 1:3000 to 1:4000 according to
international data and mostly found to be of
increased association with female gender and
gestational age >40 weeks. Despite absence of a
national program in Pakistan, individual hospitals
like Aga Khan University Hospital (AKUH)
and Shifa International have made an attempt to
screen for CH. In the first two years of screening
all newborns delivered at AKUH and four other
maternity homes working under umbrella of
AKUH were targeted, which included 5,000
births. The first report that was published in JPMA
1989 covers the initial 5000 children screened
at AKUH and 997 babies screened at Shifa
international over a three year period showing an
incidence of 1:1000 for CH. Further in 2008, an
audit of CH screening results was published from
AKUH covering the data on 53,619 total births
where TSH was done on 41,816 newborns out of
which 10 cases were detected to be suffering from
CH and an incidence of 1:16000 was reported.
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The goal of newborn screening programs is to
detect and start treatment within the first 1–2
weeks of life. Treatment consists of a daily dose
of thyroxine, available as a small tablet. The tablet
is crushed and given to the infant with a small
amount of water or milk. The most commonly
recommended dose range is 10-15 μg/kg daily,
typically 37.5 or 44 μg (Table 1). Within a few
weeks, the T4 and TSH levels are rechecked
to confirm that they are being normalized by
treatment. As the child grows up, these levels
are checked regularly to maintain the right dose.
Persistence of severe, untreated hypothyroidism
resulted in severe mental impairment, with
an intelligence quotient (IQ) below 80 in the
majority.
Most children born with CH and correctly treated
with thyroxine grow and develop normally in
all respects. Even most of those with athyreosis
and undetectable T4 levels at birth develop with
normal intelligence, although as a population,
academic performance tends to be below that
of siblings and mild learning problems occur in
some.

Table 1. Management of Congenital Hypothyrodism
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Congenital Adrenal Hyperplasia, an Insight of
Laboratory Data and Frequency Status
Dr Sahar Iqbal and Dr Aysha Habib Khan
Chemical Pathology
Reproduced from JCPSP

Journal of the College of Physicians and Surgeons
Pakistan 2013, Vol. 23 (5): 373-374
Congenital adrenal hyperplasia (CAH) refers
to autosomal recessive diseases resulting from
deficiency of enzymes involved in the production
of cortisol by the adrenal glands. More than 90 per
cent of cases of CAH are caused by 21-hydroxylase
enzyme deficiency (21OHD). Severe deficiency
produces classical form of CAH with ambiguous
genetalia and salt wasting. However, mild deficiency
of enzyme causes hidden late onset or non-classical
CAH with non-specific presentation including
hirsutism, acne, amenorrhea or infertility at later
childhood, adolescence or after puberty.
Neonatal screening program for blood 17 OHP levels
are intended to identify CAH cases of classical
and non-classical forms in affected children before
complication of salt wasting crises arises and for
early diagnosis of late non-specific presentation,
respectively. Screening of non-classical CAH
through testing blood 17 OHP levels is corner stone
for early diagnosis as disease presentation is nonspecific as well as late in onset. Levels of 17 OHP >4
ng/ml is characteristic feature for disease suspicion
in non-classical form in contrast to the diagnostic
levels of 200 ng/ml in classical form of CAH.
The non-classic form is one of the most common
autosomal recessive diseases in some ethnic groups
and one of the reasons of high prevalence of CAH
is high rates of inter-marriages among same ethnic
groups. Frequency of CAH is not known in Pakistan
but expected to be high due to increase rates of
consanguineous marriages. The rationale of this is
to determine the frequency of CAH among different
age groups, gender and distribution in four provinces
of Pakistan by evaluating the laboratory data of
baseline blood 17-hydroxyprogesterone (17 OHP)
levels. The findings of the report are presented in
Table 1.
In a retrospective analysis, laboratory data of
5853 samples tested for blood 17 OHP levels was
22

examined. The samples were collected between
period of 2007 to 2010, at the main laboratory of
AKUH in Karachi and its 188 phlebotomy centers
located in four provinces of Pakistan. Subjects
of all ages and gender were included with first
time and baseline 17 OHP blood levels performed
at clinical laboratory. Those were excluded with
any follow up blood 17 OHP levels or stimulated
with adrenocorticotropic hormone. On the basis
of exclusion criteria data was edited for subject’s
replication and a total of 2282 subjects were
recruited with non-probability purposive sampling
technique for final analysis. 17OHP results were
grouped on the basis of locations of subjects, from
where the test was ordered into Sindh, Baluchistan,
Punjab and Khyber Pakhtunkhwan (KPK). Subjects
were further categorized into four different age
groups and three gender groups and frequency was
observed for each age group and gender.
Our data showed an annual increasing frequency of
blood 17 OHP levels screening (16.3 per cent, 16.9
per cent, 20.4 per cent and 46.4 per cent through the
years from 2007 to 2010 respectively). Similarly
an increasing trend was also seen annually, for
frequency of subjects with suspected CAH (blood 17
OHP levels ≥ 4ng/ml) as 5.1 per cent, 6.5 per cent,
7.1 per cent and 15.7 per cent respectively through
the years 2007 to 2010. In general, screening for
CAH was observed to perform for different age
groups and genders. However, first time screening
was predominantly performed in female population
and after 15 years.
Overall, 34.4 per cent subjects were observed to
have 17 OHP blood levels ≥ 4ng/ml with suspicion
of CAH. Majority of subjects with 17 OHP levels ≥
4ng/ml were from infant age group (≥1 month to ≤ 1
year). With respect to gender, mostly females were
found positive for suspicion of CAH in comparison
with other genders (p = 0.0001). Variable percentages
were observed for referrals of 17 OHP levels from
different provinces but majority were referred from
Sindh (73.4 per cent). The demographic details of the
subjects are shown in Table 1.
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Table 1. Demographic features and Distribution of subjects among different Provinces of Pakistan Tested for Blood 17 OHP levels at
Aga Khan University Clinical Laboratory during 2007 - 2010 (n=2282)

As discussed earlier from positive cases (33.4 per cent),
most of the suspected cases were infants (14.4 per
cent), reflecting the importance of neonatal screening.
However we observed that CAH screening was most
commonly ordered in elder age group (after 15 years).
This late screening may be explained by the late
emergence of non-classical CAH signs and symptoms.
Variable frequency of referrals from different provinces
of Pakistan was observed as shown in Table 1.
Higher frequency of cases with suspected CAH was
observed from Sindh (23.7 per cent) as compared to
other provinces. The most likely reason of this higher
frequency from Sindh may be dependent on numbers of
referrals from the Province (73.4 per cent). In Sindh we
observed that from Karachi, 68 per cent of the samples
were collected from a large number of (78) phlebotomy
centers and main AKU campus. We also received 5.4
per cent of samples from others phlebotomy centers
located in different cities of Sindh other than Karachi,
but we found Karachi city as the main hub for 17 OHP
referrals from Sindh province, which may be due to
large number of phlebotomy centers. However, beside
AKU clinical laboratory, the blood testing of 17 OHP is
also offered by other laboratories in Punjab and Sindh.
From this laboratory data we could not conclude about
the ethnicity of subjects with blood 17 OHP ≥ 4 ng/dl,
but it could be presumed that CAH exists throughout
the country with variable frequency. This finding was

also supported by the results of a previous study from
Pakistan where Khan et al also reported presence of
CAH in different ethnic groups.
The importance of establishing neonatal screening
programme for CAH is enhanced by our present
data. However, the benefits of screening for any
disease in a state are dependent on the existing
healthcare system. The treatment or management
of inborn disorders has not been acknowledged
appropriately in Pakistan. Additionally the existing
healthcare system generally does not address
complex issues commonly seen in genetic disorders
including CAH patients.
In conclusion, the present laboratory data first time
determine the frequency of suspected CAH (33.4
per cent) in Pakistan. However, incidence of CAH
remains unidentified due to absence of new born
screening program, diagnostic testing, and lack of
disease awareness in the society and failure of case
identification by primary physician. The need of
developing a team of expertise is crucial for early
identification and management of CAH to reduce
the morbidity and mortality. A well-structured and
appropriate screening program should be instituted.
The establishment of CAH registry is also critical at
regional or national levels for the identified cases and
respective prenatal treatment.
23
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About Cystic Fibrosis
Dr Zeeshan Ansar Ahmed and Dr Lena Jafri
Molecular Pathology and Chemical Pathology

Cystic fibrosis (CF) is an autosomal recessive
genetic disorder that affects lungs, pancreas, liver,
and intestine. CF is caused by a mutation in the
gene for the protein cystic fibrosis transmembrane
conductance regulator (CFTR). This protein is
required to regulate the components of sweat,
digestive fluids, and mucus. CFTR regulates the
movement of chloride and sodium ions across
epithelial membranes, such as the alveolar epithelia
located in the lungs.
Discovery of CFTR Gene
This gene localized to 7q21-34 on long arm
chromosome 7, was discovered in 1985 and its gene
sequencing was done in 1989. The gene shown to
encode a 1480 amino acid protein, CFTR. This protein
has long linkage of amino acids, where they play the
role of a brick/block. If any of these bricks are missing
or abnormal, then the protein may not work properly.
More than 1500 CF mutations have been reported, many
of which are rare and some of which may not result in
clinical signs or symptoms. The various mutations affect
the function of CFTR in different ways.
Mode of inheritance and Risk of Passing on the
CF Gene
CF has a simple Mendelian autosomal recessive
inheritance pattern (Fig. 1). This shows that people

Fig. 1. Simple Mendelian Autosomal Recessive Inheritance. Affected
individuals will have two copies of the Mutant CFTR Gene, one Inherited
from each parent.

with CF have two copies of the mutant CFTR
gene, one inherited from each parent. Carriers have
one normal and one mutant CFTR gene and their
health is not affected because the normal CFTR
24

gene ensures production of enough protein to allow
normal cellular function. Carriers have a 50 per cent
chance of passing their mutant CFTR gene onto their
children. When both parents are carriers there is a 25
per cent chance in every pregnancy that the child will
have CF, a 25 per cent chance that the child will have
two normal CFTR genes and a 50 per cent chance
that the child will be a carrier.
At Aga Khan University Hospital Clinical
Laboratory have the facility of Delta F508 mutation
and sweat conductivity tests for cystic fibrosis.
Sweat Testing
It is recommended that sweat conductivity, which is
related to the concentration of all ions, not just chloride,
should only be used as a screening test. Several recent
studies have demonstrated that measurement of sweat
conductivity can reliably differentiate patients with CF
from those without the condition.
Precautions: Because of a report of transient
elevations in sweat electrolyte concentrations in
the first 24 hours after birth, it is recommended that
patients be at least 48 hours old before undergoing
a sweat test. Before starting the procedure it should
be made sure that the child is physiologically
and nutritionally stable, well hydrated, is not
suffering from any acute illness and is not on
mineralocorticoids. The skin should be free of cuts,
rashes and inflammation.
Technique: It occurs in three phases: sweat
stimulation, sweat collection and sweat analysis.
Localized sweating is produced by iontophoresis
of the cholinergic drug into an area of skin (usually
forearm). Macroduct sweat collector is placed
over the stimulated area and firmly strapped
to the forearm for at least thirty minutes. After
attachment, sweat becomes visible in the spiral tube
of Macroduct within one to four minutes, depending
on the relative elasticity of the skin and the subjects
sweating rate. The emergent sweat is turned blue by
contact with a small amount of blue water soluble
dye applied to the Macroduct collection surface.
Sweat collected is then analyzed in the Wescor’s
conductivity cell.
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Interpretation: 0-60 mmol/L - normal
		 60-80 mmol/L - a possible indication of CF
		 >80 mmol/L - definitive indication of CF
Failure to produce sweat: An insufficient sweat
sample is not uncommon. It can be due to several
factors such as dehydration, illness, age, race,
skin condition, and issues in collection system.
Differences in skin resistance because of ethnicity or
individual patient variability may lead to insufficient
sample volume. For example, in the United States a
higher prevalence of ‘quantity not sufficient’ samples
have been reported with black patients than with
white patients.

its major normal function is to act as a channel
through which chloride ions can pass in and out of
the cell.
Detection of Mutation, Delta F508 in CF
DNA is extracted from blood and amplified by
ARMS PCR. ARMS assay comprises two reaction,
that is identification of specific mutation by two
primers, one complementary to normal and other to
the mutant DNA sequences. The amplified product
is separated by agarose gel electrophoresis Fig. 2.

Significance of Δ F508
In all CF mutations, the most common worldwide
mutation is delta F508, which is around 70-82
per cent. it is more common in western countries
but also seen in other ethnic groups but the range
of mutations are different e.g. in Ashkenazi
Jews delta F508 accounts for 27 per cent and
W1282X for 51per cent of the mutations. Delta
F508 mutation is a three base-pair deletion in
exon 10 of the CFTR gene results in the omission
of phenylalanine (one of the bricks) at position
508 in the 1480 amino acid chain. A mutant
CFTR protein which cannot be folded into its
proper shape is produced. The quality control
mechanisms within the cell destroy this abnormal
protein before it can reach the cell surface where

Lane1

Lane2 Lane3 Lane4 Lane5 Lane6 Lane7

Fig. 2. Detection of Mutation, Delta F508

Normal allele contain 160 base pairs (bp) band
with internal control (429 bp), Homozygous
case shows mutant alleles (157bp) but in
Heterozygous case in both normal and mutant
allele seen.(Lane one & five are patient, two
& six negative control , three & seven positive
control for both normal & mutant allele and
lane four is band size marker).

Inauguration of Biochemical Genetics
Laboratory: A Step to Strengthen Diagnostic
Facilities
Dr Farhan Javed Dar
Chemical Pathology

Aga Khan University Hospital (AKUH) always
strives to introduce new Service Excellence
projects to improve quality care. Introducing the
laboratory diagnostic services for Inborn Error of
Metabolism (IEM) in Pakistan is one of the major
achievement of Clinical Laboratory in the current
year (2013). State-of-the-art techniques such as

high performance liquid chromatography (HPLC)
and gas chromatography and mass spectrometry
(GC-MS) are introduced for detection of IEM
disorders.
To make it happen, in the year 2011, a team of
Chemical Pathologists comprising of Dr Farooq
25
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Group photo during training at IMR Malaysia; Sep’ 2012
Courtesy of Dr Aysha Habib Khan

Ribbon cutting ceremony by Mr Nadeem Mustafa Khan, Dr Mohammad
Khurshid and Dr Naila Kayani

Ghani and Dr Imran Siddiqui collaborated with
Institute of Malaysia Research (IMR). This research
institute is a specialized center for IEM testing,
headed by Dr Zabedah Md Yunus, a Chemical
Pathologist of Malaysia.

Oncology inaugurated Section of Biochemical
Genetics laboratory followed by a cake cutting
ceremony. The inauguration ceremony was
attended by Dr Naila Kyani and renowned
pediatricians Drs Iqtidar Khan, Shahnaz Ibrahim,
Bushra Afroze as well as other key officials of
AKUH including Dr Nadeem Ahmed, Dr Zafar
Sajjad, Mr Sohail Baloch at the Section of
Chemical Pathology, Department of Pathology
and Microbiology.

In the first phase, two senior technologists and one
pathologist from the section of Chemical Pathology
visited IMR for four weeks training in October 2011
on amino acids and organic acids chromatograms. In
the next phase, Dr Aysha Habib Khan, went to IMR,
Malaysia for training in September 2012 to improve
and strengthen this service.

Mr Nadeem Mustafa Khan Regional CEO, Health
Services, Asia (AKUH, Pakistan and FMIC,
Afghanistan) and Dr Mohammad Khurshid,
Professor and Founding Chair Department of

The inauguration ceremony was followed by
Continuing Medical Education Seminar at the
Auditorium of AKU. Dr Farooq Ghani emphasized
during the CME seminar that the introduction of
highly sophisticated chromatographic techniques
has now made it possible to test a newborn for
several genetic metabolic disorders simultaneously
and informed the audiences how prompt detection
substantially improves the prognosis for many
of these conditions. Dr Bushra Afroze, metabolic
physician at the AKUH was of the view that an

Cake cutting ceremony

Dr Bushra Afroze, Consultant Clinical Geneticist, Assistant Professor,
Department of Paediatics and Child Health

On March 20th 2013 an official inauguration
ceremony of section of Biochemical Genetics
Laboratory was held.
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affected baby could be treated and had every
chance of growing normally. Dr Aysha Habib,
the Head of the Section of Chemical Pathology
at the AKUH, highlighted the issues and
challenges and stressed on need for groups to
work collaboratively, complementing each other’s
capabilities and sharing training resources. The
CME was inspired by the words of encouragement
by the chief guest Professor of Pediatiorcs and
Child Health, Dr Anita Zaidi.

The ceremony and seminar ended with closing
remarks of Professor Dr Naila Kayani, chairperson
of the Department of Pathology and Microbiology
and Director AKUH Clinical Laboratories. She
lauded AKUH Clinical Laboratories for successfully
initiating testing for diagnosis of IEM on stateof-the-art equipment, adding that this was another
milestone after the launch of Pakistan’s first fully
automated biochemistry laboratory at AKUH,
Karachi in 2012.

Workshop on “Inborn Errors of Metabolism”
Problem Based Learning
‘Nutricia Advanced Medical Nutrition’ conducted
full day workshops on Inborn Errors of Metabolism
(IEM) in Karachi and Islamabad on 30th November
and 2nd December 2013. Young pediatricians were
welcomed by Global Product Manager of Nutricia
Turkey, Mr A. Cem Atey. Then Ms Negar Esmailzadeh, Medical Affairs Manager of Nutricia, Turkey
provided a global perspective of IEM followed by an
interactive overview by Dr. Bushra Afroze, Consultant Clinical Geneticist and Assistant Professor
Department of Pediatrics and Child Health, AKUH.
Dr. Lena Jafri, Instructor Department of Pathology
and Microbiology, AKUH educated the participants
on collection of critical samples in suspected IEM
disorders. This was further elaborated by Dr Bushra
Afroze who conducted a session on ‘How to Deal
with Metabolic Emergencies’. The second half of the
conference commenced with Dr. Lena Jafri’s session
on ‘What Pediatricians Need to Know about Urine
Organic Acid and Plasma Amino Acid Analysis’.

The latter half of the session was dedicated to group
sessions on real life IEM cases. The objective of the
conference, to create awareness and build capacity in
young doctors of the two metropolitan cities concerning the diagnosis and management of IEM was
effectively achieved.

Group picture of Workshop Facilitators and Nutricia representatives
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